OSL — Oncosil Medical Income Statement
0.000.00%
Last trade - 00:00- AU$24.10m
- AU$19.06m
- AU$1.26m
Annual income statement for Oncosil Medical, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.38 | 1.07 | 0.43 | 0.583 | 1.26 |
| Cost of Revenue | |||||
| Gross Profit | 0.42 | 0.101 | -1.16 | -0.927 | -0.992 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11.7 | 11.6 | 11.7 | 12.5 | 16.3 |
| Operating Profit | -10.3 | -10.6 | -11.3 | -11.9 | -15 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -10.4 | -10.7 | -11.3 | -11.9 | -15.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.4 | -10.7 | -11.3 | -11.9 | -15.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.4 | -10.7 | -11.3 | -11.9 | -15.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.4 | -10.7 | -11.3 | -11.9 | -15.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.92 | -4.06 | -3.79 | -2.15 | -1.38 |